000179572 001__ 179572
000179572 005__ 20241220120850.0
000179572 0247_ $$2doi$$a10.1002/gcc.23047
000179572 0247_ $$2pmid$$apmid:35430765
000179572 0247_ $$2ISSN$$a1045-2257
000179572 0247_ $$2ISSN$$a1098-2264
000179572 0247_ $$2altmetric$$aaltmetric:126799130
000179572 037__ $$aDKFZ-2022-00750
000179572 041__ $$aEnglish
000179572 082__ $$a610
000179572 1001_ $$0P:(DE-He78)c741dc7f974390ad4310349f29aac40b$$aBochtler, Tilmann$$b0$$eFirst author$$udkfz
000179572 245__ $$aPrognostic Impact of Copy Number Alterations and Tumor Mutational Burden in Carcinoma of Unknown Primary.
000179572 260__ $$aNew York, NY$$bWiley-Liss$$c2022
000179572 3367_ $$2DRIVER$$aarticle
000179572 3367_ $$2DataCite$$aOutput Types/Journal article
000179572 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1657618799_24400
000179572 3367_ $$2BibTeX$$aARTICLE
000179572 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000179572 3367_ $$00$$2EndNote$$aJournal Article
000179572 500__ $$a#EA:A360#LA:A360# / 2022 Sep;61(9):551-560
000179572 520__ $$aChromosomal aberrations are known to drive metastatic spread, but their profile is still elusive in carcinoma of unknown primary (CUP). Therefore, it was the aim of this study to characterize the chromosomal aberration pattern in CUP depending on histological and clinical features and to assess its prognostic impact together with chromothripsis, tumor mutational burden (TMB), microsatellite instability (MSI) and mutational profiles as potential prognostic biomarkers.Chromosomal aberrations and chromothripsis were detected by methylation-based copy number variation (CNV) analysis, whereas TMB and MSI were calculated based on large next generation sequencing (NGS) panels. Putative primaries were assigned by consensus between two independent oncologists.CNV losses varied depending on putative primaries and were more abundant in patients harboring TP53 mutations and/or deletions 17p. CNV loss was prognostically adverse in localized CUP treated with surgery and/or radiotherapy, but not in disseminated poor risk CUP treated with palliative chemotherapy. CNV loss also worsened the prognosis in squamous cell CUP. Chromothripsis was detected in 18/59 (30.5%) patients without prognostic effect. TMB was highest in cases with microsatellite instability, squamous cell histology and with lung, anal or cervical putative primaries.Overall, CNV, chromothripsis, TMB and MSI profiles in CUP are reminescent of biological characteristics known from other cancer entities without a unifying CUP-specific signature. Markedly, high-level CNV loss is an adverse predictive biomarker in localized but not disseminated chemotherapy treated CUP. This implies that chromosomal losses drive CUP progression, but also increase susceptibility to chemotherapy, with both effects apparently leveling out in disseminated CUP.
000179572 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000179572 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000179572 650_7 $$2Other$$aCarcinoma of unknown primary (CUP)
000179572 650_7 $$2Other$$achromosomal instability
000179572 650_7 $$2Other$$achromothripsis
000179572 650_7 $$2Other$$acopy number variations (CNV)
000179572 650_7 $$2Other$$amutational profile
000179572 650_7 $$2Other$$aprognosis
000179572 650_7 $$2Other$$atumor mutational burden (TMB)
000179572 7001_ $$0P:(DE-He78)de9da69e07eba6d0ca82a4f087a64a28$$aWohlfromm, Timothy$$b1$$udkfz
000179572 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b2$$udkfz
000179572 7001_ $$0P:(DE-He78)d20d08adc992abdb6ccffa1686f1ba17$$aStichel, Damian$$b3$$udkfz
000179572 7001_ $$0P:(DE-He78)d62d536fb73eb7644201ddaac56cf68f$$aPouyiourou, Maria$$b4$$udkfz
000179572 7001_ $$0P:(DE-He78)a3903480c7232195efbd7b0f6f8564e8$$aKraft, Bianca$$b5$$udkfz
000179572 7001_ $$aNeumann, Olaf$$b6
000179572 7001_ $$aEndris, Volker$$b7
000179572 7001_ $$0P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$avon Deimling, Andreas$$b8$$udkfz
000179572 7001_ $$00000-0003-1001-103X$$aStenzinger, Albrecht$$b9
000179572 7001_ $$0P:(DE-He78)493c5fbf69f1b20df6f048712f3ad4a0$$aKrämer, Alwin$$b10$$eLast author$$udkfz
000179572 773__ $$0PERI:(DE-600)1492641-6$$a10.1002/gcc.23047$$gp. gcc.23047$$n9$$p551-560$$tGenes, chromosomes & cancer$$v61$$x1045-2257$$y2022
000179572 8767_ $$82022 (V10366)$$92022-06-23$$d2024-12-19$$eHybrid-OA$$jZahlung erfolgt
000179572 909CO $$ooai:inrepo02.dkfz.de:179572$$pVDB$$pOpenAPC$$popenCost
000179572 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c741dc7f974390ad4310349f29aac40b$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000179572 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)de9da69e07eba6d0ca82a4f087a64a28$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000179572 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000179572 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d20d08adc992abdb6ccffa1686f1ba17$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000179572 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d62d536fb73eb7644201ddaac56cf68f$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000179572 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a3903480c7232195efbd7b0f6f8564e8$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000179572 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000179572 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)493c5fbf69f1b20df6f048712f3ad4a0$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000179572 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000179572 9141_ $$y2022
000179572 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2021-02-03$$wger
000179572 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-03
000179572 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-03
000179572 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-03
000179572 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-17$$wger
000179572 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bGENE CHROMOSOME CANC : 2021$$d2022-11-17
000179572 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-17
000179572 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-17
000179572 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-17
000179572 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-17
000179572 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-17
000179572 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-17
000179572 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-17
000179572 915pc $$0PC:(DE-HGF)0000$$2APC$$aAPC keys set
000179572 915pc $$0PC:(DE-HGF)0001$$2APC$$aLocal Funding
000179572 9202_ $$0I:(DE-He78)A360-20160331$$kA360$$lKKE Mol. Hämatologie/Onkologie$$x0
000179572 9201_ $$0I:(DE-He78)A360-20160331$$kA360$$lKKE Mol. Hämatologie/Onkologie$$x0
000179572 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x1
000179572 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x2
000179572 9200_ $$0I:(DE-He78)A360-20160331$$kA360$$lKKE Mol. Hämatologie/Onkologie$$x0
000179572 980__ $$ajournal
000179572 980__ $$aVDB
000179572 980__ $$aI:(DE-He78)A360-20160331
000179572 980__ $$aI:(DE-He78)C060-20160331
000179572 980__ $$aI:(DE-He78)B300-20160331
000179572 980__ $$aUNRESTRICTED
000179572 980__ $$aAPC